Whole DNA sequencing reveals mutations, new gene for blinding disease
Findings for retinitis pigmentosa described in the Proceedings of the National Academy of Sciences
2013-09-17
(Press-News.org) BOSTON -- Retinitis pigmentosa (RP) is a genetic disease that causes progressive loss of vision and is caused by mutations in more than 50 genes. Conventional methods for identification of both RP mutations and novel RP genes involve the screening of DNA coding sequences.
In a paper in the Proceedings of the National Academy of Sciences, researchers from the Massachusetts Eye and Ear, Harvard Medical School, the University of Lausanne, Switzerland, and others tested DNA with the use of whole genome sequencing, a technique that takes into account all variants from both the coding and noncoding regions of the human genome. With this approach the authors report a number of unique RP mutations, a previously undescribed disease gene called NEK2 that involves the retinal photoreceptors, and structural DNA rearrangements originating in introns.
This paper supports the advantages of the use of whole genome sequencing to search for mutations in patients with RP.
The researchers performed whole genome sequencing in 16 unrelated patients with autosomal recessive retinitis pigmentosa (ARRP), a disease characterized by progressive retinal degeneration and caused by mutations in over 50 genes, in search of pathogenic DNA variants, the authors wrote. Eight patients were from North America, whereas eight were Japanese, a population for which ARRP seems to have different genetic drivers.
Using a specific work flow, they assessed both the coding and noncoding regions of the human genome, including the evaluation of highly polymorphic SNPs, structural and copy number variations, as well as 69 control genomes sequenced by the same procedures. They detected homozygous or compound het erozygous mutations in 7 genes associated with ARRP (USH2A, RDH12, CNGB1, EYS, PDE6B, DFNB31, and CERKL) in eight patients, three Japanese and five Americans. Fourteen of the 16 mutant alleles identified were previously unknown. Among these, there was a 2.3-kb deletion in USH2A and an inverted duplication of 446 kb in EYS, which would have likely escaped conventional screening techniques or exome sequencing. Moreover, in another Japanese patient, they identified a homozygous frameshift (p.L206fs), absent in more than 2,500 chromosomes from ethnically matched controls, in the ciliary gene NEK2, encoding a serine/threonine-protein kinase. Inactivation of this gene in zebrafish induced retinal photoreceptor defects that were rescued by human NEK2mRNA. In addition to identifying a previously undescribed ARRP gene, the study highlights the importance of rare structural DNA variations in Mendelian diseases and advocates the need for screening approaches that transcend the analysis of the coding sequences of the human genome.
###
This work was supported by the Swiss National Science Foundation (Grant 310030_138346) and the Gebert Rüf Foundation, Switzerland (Rare Diseases-New Technologies Grant); a Center Grant from the Foundation Fighting Blindness; National Institutes of Health Grants DK072301 and MH-084018; Ministry of Health, Labor and Welfare of Japan Grant 23300101 and Grant 23300201; the Japan Science and Technology Agency, and the Strategic Research Program for Brain Sciences; and a Grant-in-Aid for Scientic Research on Innovative Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan and Takeda Science Foundation. A full list of authors and their contributions to the research is available in the paper.
About Massachusetts Eye and Ear
Mass. Eye and Ear clinicians and scientists are driven by a mission to find cures for blindness, deafness and diseases of the head and neck. After uniting with Schepens Eye Research Institute Mass. Eye and Ear in Boston became the world's largest vision and hearing research center, offering hope and healing to patients everywhere through discovery and innovation.
Mass. Eye and Ear is a Harvard Medical School teaching hospital and trains future medical leaders in ophthalmology and otolaryngology, through residency as well as clinical and research fellowships. Internationally acclaimed since its founding in 1824, Mass. Eye and Ear employs full-time, board-certified physicians who offer high-quality and affordable specialty care that ranges from the routine to the very complex. U.S. News & World Report's "Best Hospitals Survey" has consistently ranked the Mass. Eye and Ear Departments of Otolaryngology and Ophthalmology as top five in the nation.
ELSE PRESS RELEASES FROM THIS DATE:
2013-09-17
Vaccinating cattle against the E. coli O157 bacterium could cut the number of human cases of the disease by 85%, according to scientists.
The bacteria, which cause severe gastrointestinal illness and even death in humans, are spread by consuming contaminated food and water, or by contact with livestock faeces in the environment. Cattle are the main reservoir for the bacterium.
The vaccines that are available for
cattle are rarely used, buc could be significant.
The research was lead by a team of researchers at the University of Glasgow in collaboration with the ...
2013-09-17
Copper bracelets and magnet wrist straps have no real effect on pain, swelling, or disease progression in rheumatoid arthritis, according to new findings from a study conducted at the University of York.
In the first randomised controlled trial to study the effects of copper bracelets and magnetic wrist straps on rheumatoid arthritis, 70 patients with active symptoms each wore four different devices over a five-month period, reporting on their pain, disability, and medication use throughout the study. Participants also provided blood samples, after wearing each device ...
2013-09-17
BOSTON -- Young women with breast cancer often overestimate the odds that cancer will occur in their other, healthy breast, and decide to have the healthy breast surgically removed, a survey conducted by Dana-Farber Cancer Institute investigators indicates. The survey also shows that many patients opt for the procedure -- known as a contralateral prophylactic mastectomy, or CPM -- despite knowing it will be unlikely to improve their chance of survival.
The study, published in the Sept. 17 issue of the Annals of Internal Medicine, shows a certain disconnect between ...
2013-09-17
LA JOLLA, Calif., September 16, 2013 – Scientists at Sanford-Burnham Medical Research Institute (Sanford-Burnham) today announced the discovery that a gene encoding an enzyme, phosphoinositide-dependent kinase-1 (PDK1), plays an essential role in the development and progression of melanoma. The finding offers a new approach to treating this life-threatening disease.
The team of researchers, led by Ze'ev Ronai, Ph.D., professor and scientific director of Sanford-Burnham Medical Research Institute in La Jolla (San Diego, Calif.), used genetic mouse melanoma models to show ...
2013-09-17
Researchers at the Vanderbilt Heart and Vascular Institute and Massachusetts General Hospital have identified a biomarker that can predict diabetes risk up to 10 years before onset of the disease.
Thomas J. Wang, M.D., director of the Division of Cardiology at Vanderbilt, along with colleagues at Massachusetts General Hospital, report their findings in the October issue of The Journal of Clinical Investigation.
The researchers conducted a study of 188 individuals who developed type 2 diabetes mellitus and 188 individuals without diabetes who were followed for 12 years ...
2013-09-17
Humberto is the second "zombie" tropical storm of the Atlantic Ocean season. That is, it's the second tropical storm that degenerated into a remnant low pressure area only to make a comeback as a tropical storm. NASA's HS3 hurricane mission sent an unmanned Global Hawk Aircraft out to the eastern Atlantic to investigate Humberto on Sept. 16.
On Sunday, Sept. 15, Humberto weakened to a remnant low pressure area when it hit an area of strong wind shear. The wind shear eased and Humberto regained tropical storm strength on Sept. 16, making it the second "zombie" storm in ...
2013-09-17
RIVERSIDE, Calif. — Two assistant professors of management at the University of California, Riverside and several other researchers have previously shown that men with wider faces are more aggressive, less trustworthy and more prone to engaging in deception.
Now, in a just-published paper, they have shown, in a series of four studies, that individuals behave more selfishly when interacting with men with wider faces and this selfish behavior elicits selfish behavior in others.
"This clearly shows that this behavior is also socially driven, not just biologically driven," ...
2013-09-17
A group of international scientists including a Lawrence Livermore National Laboratory researcher have confirmed that life really could have come from out of this world.
The team shock compressed an icy mixture, similar to what is found in comets, which then created a number of amino acids – the building blocks of life. The research appears in advanced online publication Sept. 15 on the Nature Geosciences journal website.
This is the first experimental confirmation of what LLNL scientist Nir Goldman first predicted in 2010 and again in 2013 using computer simulations ...
2013-09-17
LEBANON, NH (Sept. 16, 2013) – Consumers should be wary when watching those advertisements for pharmaceuticals on the nightly TV news, as six out of 10 claims could potentially mislead the viewer, say researchers in an article published in the Journal of General Internal Medicine.
Researchers Adrienne E. Faerber of The Dartmouth Institute for Health Policy & Clinical Practice and David H. Kreling of The University of Wisconsin-Madison School of Pharmacy found that potentially misleading claims are prevalent throughout consumer-targeted prescription and non-prescription ...
2013-09-17
LA JOLLA, CA—September 16, 2013—Scientists at The Scripps Research Institute (TSRI) have found a way to make dramatic improvements to the cancer cell-killing power of vinblastine, one of the most successful chemotherapy drugs of the past few decades. The team's modified versions of vinblastine showed 10 to 200 times greater potency than the clinical drug. Even more significantly, these new compounds overcome the drug resistance that emerges upon treatment relapse, which renders continued or subsequent vinblastine treatment ineffective in some patients.
The TSRI researchers ...
LAST 30 PRESS RELEASES:
[Press-News.org] Whole DNA sequencing reveals mutations, new gene for blinding disease
Findings for retinitis pigmentosa described in the Proceedings of the National Academy of Sciences
